Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows
Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.
24-week interim results from the INSPIRING study presented at CROI 2018 show that dolutegravir 50 mg twice daily is effective and well-tolerated in adults with HIV/TB receiving rifampicin-based TB treatment.
Significant Interaction Between Once-Weekly Isoniazid/Rifapentine and Daily Dolutegravir: Study Stopped Due to Toxicity
Serious toxicities were seen in participants in a drug-drug interaction study of once-weekly isoniazid and rifapentine with once-daily dolutegravir, leading to its early termination.
Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.
"This is really the first step in demonstrating that two-drug regimens can be as effective as three-drug regimens," says Kimberly Smith, M.D., M.P.H.
Several studies at CROI 2017 reported a similar conclusion: reducing ART to dolutegravir monotherapy should be stopped.
Dolutegravir exposure was higher after crushing the originator fixed-dose combination tablet and after crushing was followed by enteral nutrition, compared to the whole tablet.
Dolutegravir granules-in-suspension achieved satisfactory exposures in children aged between 2 and 6 years, according to data presented at CROI2017.
Dolutegravir is safe and effective in children age 6-12 years, according to results presented at CROI 2016.